Amneal Pharmaceuticals, Inc. — Form SCHEDULE 13D/A
Filed August 12, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
A Schedule 13D/A (amended beneficial ownership statement) was filed on 2026-08-12 by Patel Tushar Bhikhubhai regarding Amneal Pharmaceuticals, Inc. The filing metadata is present but the actual amendment text—disclosing changes in ownership percentage, share count, transaction details, or beneficial ownership structure—is not legible in the provided document excerpt. Without access to the substantive disclosure, specific counterparties, dollar amounts, percentages, share counts, and dates of changes cannot be identified.
Why this rating
Schedule 13D/A amendments are routine disclosures of ownership changes. Without visible substantive content, cannot assess materiality; company scale ~$1.7B. Requires full document review.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.